Jazz Pharmaceuticals (MEX:JAZZN) ROCE %: 14.27% (As of Mar. 2026)


MEX:JAZZN Jazz Pharmaceuticals PLC MEX:JAZZN
73 GF Score
Price MXN2,500.00
GF Value MXN1,641.59
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals ROCE %?

Jazz Pharmaceuticals MEX:JAZZN 73 ROCE % is 14.27% as of Mar. 2026. GuruFocus rates MEX:JAZZN with a GF Score™ of 73/100 and a GF Value™ of MXN1,641.59. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jazz Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 14.27%.

Jazz Pharmaceuticals  (MEX:JAZZN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jazz Pharmaceuticals ROCE % Related Terms

Jazz Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals ROCE % Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.93 -0.77 5.53 7.46 -3.91

Jazz Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.09 -27.42 2.53 10.88 14.27
MEX:JAZZN
73GF Score
Jazz Pharmaceuticals PLC MEX:JAZZN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals ROCE % Calculation

Jazz Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-7793.011/( ( (250524.028 - 21660.167) + (209934.578 - 40378.16) )/ 2 )
=-7793.011/( (228863.861+169556.418)/ 2 )
=-7793.011/199210.1395
=-3.91 %

Jazz Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=24459.556/( ( (209934.578 - 40378.16) + (213860.609 - 40512.264) )/ 2 )
=24459.556/( ( 169556.418 + 173348.345 )/ 2 )
=24459.556/171452.3815
=14.27 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 14.27% mean?
Jazz Pharmaceuticals (MEX:JAZZN) has a ROCE % of 14.27% as of Mar. 2026.
Is Jazz Pharmaceuticals' ROCE % too high?
Jazz Pharmaceuticals' current ROCE % is 14.27%. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' ROCE % compare to ASND and SMMT?
Jazz Pharmaceuticals' ROCE % of 14.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Jazz Pharmaceuticals's current ROCE % is 14.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Jazz Pharmaceuticals (MEX:JAZZN) has a current ROCE % of 14.27%. The stock's GF Value™ is MXN1,641.59, compared to a current price of MXN2,500.00 — trading 52.3% above its estimated fair value. The current ROCE % is 14.27%. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Jazz Pharmaceuticals (MEX:JAZZN), the current ROCE % is 14.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (MEX:JAZZN) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of MXN2,500.00 is trading 52.3% above its estimated GF Value™ of MXN1,641.59.

Key valuation signals for MEX:JAZZN:

  • ROCE %: 14.27%
  • GF Value™: MXN1,641.59 vs. price of MXN2,500.00 (52.3% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the MEX:JAZZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for MEX:JAZZN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,500.00
Price
MXN1,641.59
GF Value